The Global Drug sales of Enbrel stood at USD 4,527 Millions in 2023
The indicator recorded a historical decline (CAGR) of11% between 2020 to 2023 and is expected to decline by ...
GlobalData projects the indicator to decline at a CAGR of...
Etanercept (Enbrel), is a dimeric fusion protein, immunomodulator and an antirheumatic agent. It is formulated as solution and powder for solution for subcutaneous route of administration.
Mechanism of Action
Etanercept is a human tumor necrosis factor receptor p75 fc fusion protein produced by recombinant DNA technology in a chinese hamster ovary (CHO) mammalian cell expressing system. Etanercept inhibits binding of both TNF alpha and TNF beta (lymphotoxin alpha [LT aplha]) to cell surface TNFRs, rendering TNF biologically inactive.
Enbrel Overview
Enbrel is indicated for the treatment of moderate to severe active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis (JIA) in patients ages 2 and older and active ankylosing spondylitis (AS). It is also indicated for reducing signs and symptoms, inhibiting the progression of structural damage of active arthritis, and improving physical function in patients with psoriatic arthritis (PsA). Enbrel can be used with or without methotrexate (MTX) in the treatment of psoriatic arthritis. In addition, it is also used for the treatment of adult patients (18 years or older) with chronic moderate to severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy and plaque psoriasis in pediatric patients. Enbrel for pediatric use injection is only used for juvenile idiopathic arthritis and pediatric plaque psoriasis. Enbrel is indicated for the treatment of patients 4 to 17 years with chronic moderate to severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy. It is also indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (jia) in patients aged 4 to 17 years who have had an inadequate response to one or more disease-modifying antirheumatic drugs (DMARDs). Enbrel has not been studied in children less than 2 years of age. It is indicated for the treatment of non-radiographic axial spondyloarthritis.
Enbrel was first approved in 1998 and is sold globally including the US, the UK, France, Germany, and Japan by several pharma giants including Amgen Inc, Pfizer Inc, Takeda Pharmaceutical Co Ltd, and Immunex Corp. Enbrel drug sales include the historical sales that are derived from company financial reports, and consensus forecasts are calculated based on company-specific broker reports as well as GlobalData’s proprietary methodology.
United States of America
China
United States of America
United States of America
United States of America
United States of America
United Kingdom
Switzerland
France
Germany
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer